Summary
A bioRxiv preprint describes two patient-derived anti-HPA-1a antibodies and finds that one induced platelet aggregation through coordinated binding to HPA-1a and FcγRIIa. The laboratory study provides a mechanistic explanation for functional differences among antibodies involved in fetal and neonatal alloimmune thrombocytopenia.
A patient-derived antibody involved in fetal and neonatal alloimmune thrombocytopenia (FNAIT) induced platelet aggregation through a mechanism requiring two forms of binding at the same time, according to a bioRxiv preprint posted on September 15, 2026.
The researchers structurally and functionally characterised two monoclonal anti-HPA-1a antibodies, named D-204 and M-204, obtained from a mother whose pregnancy was affected by severe FNAIT. Only M-204 induced platelet aggregation in the experiments. The finding identifies a specific interaction between the antibody, the platelet antigen HPA-1a and the platelet receptor FcγRIIa that may help explain why anti-HPA-1a antibodies can produce different biological effects.
Why anti-HPA-1a antibodies matter in FNAIT
FNAIT occurs when maternal alloantibodies recognise a human platelet antigen inherited by the fetus from the father. These antibodies can cross the placenta and bind to fetal platelets, reducing the platelet count. Severe disease can include intracranial haemorrhage. Anti-HPA-1a antibodies are the main antibody group associated with FNAIT, but individual antibodies can differ in the part of the antigen they recognise and in their glycosylation, a chemical modification that can affect antibody behaviour.
The study focused on antibodies that bind αIIbβ3, the platelet surface protein carrying the HPA-1a target. Antibodies have antigen-binding Fab arms and an Fc region that can interact with immune-cell receptors. FcγRIIa is also found on platelets and can transmit signals that contribute to platelet activation when it is engaged in the appropriate antibody-dependent context.
This distinction matters because the presence of an anti-HPA-1a antibody alone may not describe its functional behaviour. The authors used the two patient-derived antibodies alongside previously characterised anti-HPA-1a antibodies, including B2G1 and 26.4, to examine these differences.
M-204 required two coordinated interactions
Flow-cytometry experiments showed that M-204 bound αIIbβ3 with different binding kinetics from D-204 and the comparison antibodies. M-204 reached only half-maximal binding under the reported assay conditions. Despite that pattern, it was the only antibody in the comparison that induced platelet aggregation.
To investigate the mechanism, the researchers produced several altered antibody formats: Fab, Fab2, bispecific and an IgG variant with an Fc region unable to carry out its normal receptor-binding function. The experiments showed that aggregation required both Fab arms to engage HPA-1a and also required intact binding to FcγRIIa.
In other words, M-204 needed to connect the platelet antigen through both of its antigen-binding arms while retaining an active Fc region capable of engaging FcγRIIa. Structural models and crystal structures supported this interpretation. The authors report that this dual engagement is a distinctive feature of M-204 among the HPA-1 monoclonal antibodies examined.
The work is a laboratory structural and functional study rather than a clinical treatment or intervention study. Its main contribution is a molecular explanation for how one patient-derived anti-HPA-1a antibody can activate platelets, while closely related antibodies may behave differently. That functional diversity could be important when researchers investigate why FNAIT severity is difficult to predict from antibody presence alone.
The report is available as a bioRxiv preprint, so the findings represent an early research result. Further work would be needed to determine how consistently this mechanism operates across patients and how it relates to clinical disease severity.